Vor Biopharma (NASDAQ:VOR) Upgraded at Wall Street Zen
by Scott Moore · The Cerbat GemWall Street Zen upgraded shares of Vor Biopharma (NASDAQ:VOR – Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Saturday morning.
A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Vor Biopharma in a research note on Monday, March 30th. They issued a “buy” rating and a $50.00 price target on the stock. Wedbush upped their price target on shares of Vor Biopharma to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Citigroup initiated coverage on shares of Vor Biopharma in a research note on Friday, January 9th. They issued a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. dropped their price target on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Finally, TD Cowen initiated coverage on shares of Vor Biopharma in a research note on Wednesday, December 17th. They issued a “buy” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.67.
Read Our Latest Stock Report on Vor Biopharma
Vor Biopharma Stock Down 9.9%
Shares of NASDAQ:VOR opened at $16.27 on Friday. The company’s fifty day moving average is $14.25 and its two-hundred day moving average is $17.35. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80. The company has a market cap of $794.79 million, a P/E ratio of -0.04 and a beta of 1.92.
Insider Transactions at Vor Biopharma
In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 589,257 shares of Vor Biopharma stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the sale, the director directly owned 4,555,741 shares in the company, valued at $75,579,743.19. The trade was a 11.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.45% of the stock is owned by company insiders.
Hedge Funds Weigh In On Vor Biopharma
Hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. bought a new stake in Vor Biopharma during the fourth quarter valued at about $36,000. Squarepoint Ops LLC bought a new stake in Vor Biopharma during the third quarter valued at about $230,000. Bank of America Corp DE boosted its holdings in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock valued at $232,000 after acquiring an additional 4,144 shares during the period. BNP Paribas Financial Markets boosted its holdings in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after acquiring an additional 5,058 shares during the period. Finally, Bridgeway Capital Management LLC bought a new stake in Vor Biopharma during the third quarter valued at about $304,000. 97.29% of the stock is owned by institutional investors and hedge funds.
Vor Biopharma Company Profile
Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.
The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).